Details of the Drug Combinations

General Information of This Drug (ID: DMGQIPT)

• Drug Name: Caspofungin (DMGQIPT)
• Synonyms: CASPO; Cancidas; Capsofungin; Caspofungin [INN]; M991; Cancidas (TM); Cancidas (TN); Caspofungin (INN); MK-0991; L-743,872; [1(R)-hydroxyethyl]-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0(9,13)]heptacosane-2,5,8,14,17,23-hexaone diacetate; Pneumocandin B0, 1-[(4R,5S)-5-[(2-aminoethyl)amino]-N2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-(9CI); (4R,5S)-5-((2-Aminoethyl)amino)-N(sup 2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide; (4R,5S)-5-((2-aminoethyl)amino)-N(2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide; 1-[(4R,5S)-5-[(2-aminoethyl)amino]-N(2)-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-pneumocandin B0

Indication

Candidiasis; ICD 11: 1F23; Status: Approved [1]; Fungal infection; ICD 11: 1F29-1F2F; Status: Approved [2]; Mycoses; ICD 11: 1F2Z; Status: Approved [1]; Mycosis fungoides; ICD 11: 2B01; Status: Approved [1]; Candidemia; ICD 11: 1F23.3Y; Status: Investigative [1]; Esophageal candidiasis; ICD 11: N.A.; Status: Investigative [1]

• Therapeutic Class: Antifungal Agents
• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

5 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
F901318 + Caspofungin	DC1OFN0	F901318	Pulmonary Aspergillosis - Invasive	[3]
Voriconazole + Caspofungin	DC8YKF6	Voriconazole	Infection	[4]
Voriconazole + Caspofungin	DCER6ES	Voriconazole	Candidiasis, Invasive	[5]
Caspofungin + SCY-078	DCE2X0G	SCY-078	Candidiasis, Invasive	[6]
Caspofungin + Fluconazole	DCU1WYY	Fluconazole	Candidiasis, Invasive	[6]

References

• [1] Caspofungin FDA Label
• [2] Echinocandins: pharmacokinetic and therapeutic issues. Curr Med Res Opin. 2009 Jul;25(7):1741-50.
• [3] ClinicalTrials.gov (NCT02856178) Study on Safety and Pharmacokinetics of Intravenous F901318 for Fungal Prophylaxis in AML Patients
• [4] ClinicalTrials.gov (NCT00238355) Voriconazole and Caspofungin Acetate in Treating Invasive Fungal Infections in Patients With Weakened Immune Systems
• [5] ClinicalTrials.gov (NCT00413218) Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
• [6] ClinicalTrials.gov (NCT05178862) A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole